Arkolith/Insider Trading/INZY/Form 4

Bolte Axel

Chief Executive Officer, DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Apr 20, 2022
Net Buying
Open-Market Buys
$250K
Open-Market Sells
$0
Net Open-Market Flow
$250K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 19, 2022Buy(P)68K$3.69$250K259K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-024917) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML